At HUPO 2010, Bruker Showcases High-Performance Mass Spectrometry Platforms and Advances in Applied Proteomics Solutions
19/09/2010 12:00pm
Business Wire
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Jul 2019 to Jul 2024
At the Human Proteome Organisation's (HUPO) 9th Annual World Congress (www.hupo2010.com),
Bruker displays leading technologies and solutions for proteomics in the
next decade. Bruker’s “Continuing Revolution” campaign
demonstrates the company’s commitment to enabling the proteomics
community to pursue an ever increasing range of scientific
investigations, as well as clinical proteomics research and emerging
applied proteomics methods:
-
The autoflex™ speed is a flexible and high performance
MALDI-TOF(/TOF) system specifically designed for enhanced workflows in proteomics
research. The fields of MALDI tissue biomarker and drug
imaging, where Bruker is leading and continually innovating, is
greatly advanced by the novel FAST-SRM mode for single reaction
monitoring capabilities. Enhanced speed and reliable operation are
delivered by the 1 kHz smartbeam™-II laser and the MALDI
Perpetual™ self-cleaning ion source, previously introduced in
Bruker’s market leading ultrafleXtreme™ MALDI-TOF/TOF.Further
enhancements on the autoflex speed as a proteomics platform for
MALDI based workflows are its wide mass range resolving power of up to
26,000 delivered by the PAN™ technology, the innovative FlashDetector™
system and the novel 4 Gs/s digitizer. Edmass™ top-down
intact protein sequencing for long sequence readouts, including
Bruker’s patented T³-Sequencing™ technology, is now fully
supported on the autoflex speed.
-
High performance molecular imaging of small molecules including
drugs, metabolites and lipids in tissue is now available on the new
unrivalled MALDI-solariX™ FTMS platform, which combines
extreme performance with resolving power > 1,000,000 at 7 tesla with
a robust and highly sensitive MALDI source. Its unique instrument
design with a dual ion funnel and quad-based ion selection
for signal enhancement by CASITM
(continuous accumulation of selected ions) provides unparalleled
sensitivity for the analysis of therapeutic doses of drugs and their
metabolites directly in tissue. Its dual ESI/MALDI source allows
easy switching between both ionization modes by simple push-button
software. Fast data acquisition of up to 1 pixel/sec with the smartbeamTM
II laser at a 1 kHz laser rate and laser spot sizes down to 20
um for high spatial resolution are essential features of this
ultimate MALDI small molecule tissue imaging system.
-
As MALDI Imaging matures as a key proteomic application, it
becomes essential to cover the complete workflow for effective and
scientifically relevant clinical research. The MALDI Molecular
ImagerTM concept, on ultrafleXtreme
and autoflex speed MALDI-TOF platforms, as well as on
the solariX MALDI-FTMS, enables non-targeted molecular
histology with high spatial resolution in an integrated solution
(research use only) for biological tissue and clinical pathology
investigations. The entire, highly effective workflow is provided by
seamless integration of the mass spectrometers with sample preparation
by the proprietary Bruker ImagePrep™ station and with the data
processing software FlexImaging™. This workflow is completed by ClinProTools™,
the first commercially available software solution for small
molecule statistical class imaging. By continuous innovation, Bruker
remains committed to the development of MALDI Imaging as a key
proteomics technology.
-
Bruker provides high performance top-down protein sequencing and
characterization workflows across a range of systems. A
breakthrough has been recently achieved in collaboration with
scientists by applying ETD on the maXis™ UHR-TOF system.
High mass accuracy, resolving power and dynamic range, essential for
the dissection of complex patterns of product ions in protein
fragmentation, have been harnessed for the first time to perform ETD
dissociation of intact biomolecules up to 150 kDa with ease. This
represents a new record for mass spectrometric sequencing of intact
proteins and demonstrates the dramatic advantages of maXis ETD
technology in top-down protein structure analysis. This achievement
underlines Bruker’s leading position in all fields of top-down
proteomics.
-
The amaZon ETD, Bruker’s 4th generation ion trap
platform, offers class leading ETD and PTR (Proton Transfer Reaction)
for unmatched sensitivity in an extremely robust setup. Ion trap mass
resolving power up to 20,000 in full scan mode across the 50-3000 m/z
range with scan speeds up to 52,000 u/sec, fast enough to be useable
for LC coupling, make real-life, routine LC-ETD experiments for PTMs a
reality.
-
MALDI-ISD (In-Source Decay), leveraging innovations
incorporated into the industry leading ultrafleXtreme and autoflex
speed MALDI-TOF(-TOF) platforms completes Bruker’s
comprehensive set of workflows as the leading supplier for top-down
protein sequencing and characterization.
-
Bruker’s ProteinScapeTM 2.1 software
is the most established proteomics bioinformatics platform addressing
scientists' needs in biomarker profiling, quantification and
validation. As a comprehensive solution for qualitative and
quantitative LC-MS/MS protein analysis, ProteinScape supports
all current label chemistries including multiplexed labels, as well as
label-free quantification. Interactive validation of protein
quantification based on raw LC/MS data is simple and straight forward.
It streamlines the discovery process through decoy auto-validation
algorithms, combined database searches with various algorithms and the ProteinExtractorTM
module that produces non-redundant protein result lists across entire
proteomics projects. Its archiving capabilities allow the retrieval of
data generated years ago, e.g. for their joint re-analysis with novel
analytic capabilities and mining tools. The ProteinScape
processing pipeline adopts the "HUPO Brain Proteomics Project
processing guidelines" (forum.hbpp.org) and will facilitate the direct
submission process of project data adhering to HUPO/PSI publishing
guidelines.
Clive Seymour, Executive Vice President of Bruker Daltonics, commented:
“As the field of proteomics evolves, Bruker continues to innovate and
deliver workflows suited to the needs of those engaged in an expanding
discipline. Offering solutions based on a broad range of technologies
and workflows without compromising performance and ease of use,
underlines the philosophy and defines our leadership in proteomics.
Whatever the application, whether it is ‘traditional’ expression
proteomics or novel fields such as top-down proteomics, tissue imaging
or quantitation with or without labels, we strive to provide the highest
performance solutions.”
In addition to supporting HUPO 2010 as a Gold Sponsor, Bruker will be
present in the scientific program with more than 40 contributions.
Bruker Daltonics staff will be available for in-depth meetings during
exhibit hours at Bruker's booth (No. 1). The Bruker Luncheon Seminars
will be held on Tuesday, September 21st, 12:30-1:30 PM, in
the Baysite Gallery Auditorium A during which a panel of prestigious
international researchers including Christoph Borchers from
ProteomeCenter, Victoria, Canada, and Keith Ashman, CNIO Madrid, Spain,
will present talks, detailing a series of innovative proteomic
applications. For more information on Bruker’s HUPO events, please visit www.bdal.com/hupo
ABOUT BRUKER DALTONICS: For more information about Bruker
Daltonics and Bruker Corporation (NASDAQ: BRKR), please visit www.bdal.com
and www.bruker.com.